TITLE PAGE

Rationale and design of the Learning Implementation of Guideline-based

decision support system for Hypertension Treatment (LIGHT) Trial and

LIGHT-ACD Trial

Short Title:

Study protocol for LIGHT and LIGHT-ACD trials

Authors:

Jiali Song, MD; Xiu-Ling Wang, MD; Bin Wang, MD; Yan Gao, MA; Jia-Min Liu, MD;

Hai-Bo Zhang, MD; Xi Li, MD, PhD; Jing Li, MD, PhD; Ji-Guang Wang, MD, PhD; Jun

Cai, MD, PhD; Jeph Herrin, PhD; Jane Armitage, FRCP, FFPH[#]; Harlan M. Krumholz,

MD, SM[#]; Xin Zheng, MD, PhD^{#†}; on behalf of the LIGHT Collaborative Group

[#]Joint senior authors

[†]Corresponding authors

Author Affiliations:

National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China (Song, X.L. Wang, B. Wang, Gao, Liu, Zhang, X. Li, J. Li, Zheng); Hypertension Center, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Page 1 of 41

> Beijing, China (Cai); The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.G. Wang); Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LF, UK (Armitage); MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (Armitage); Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, United States (Krumholz); Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States (Herrin, Krumholz); Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, United States (Krumholz).

Correspondence:

Dr. Xin Zheng, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, 167 Beilishi Road, Beijing 100037, People's Republic of China; Tel: +86 10 6086 6719; Email: xin.zheng@fwoxford.org

ABSTRACT

Background: Computerized clinical decision support systems (CDSS) are low-cost, scalable tools with the potential to improve guideline-based antihypertensive treatment in primary care, but their effectiveness needs testing in pragmatic trials. **Methods:** The Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) trial is a pragmatic, four-stage, cluster-randomized trial conducted in 94 primary care practices in China. For each city-based stage, practices are randomly assigned to either implementation of the CDSS for hypertension management (which guides physicians treatment recommendations based on measured blood pressure and patient characteristics), or usual care. Patients are enrolled during the first 3 months after site randomization and followed for 9 months. The primary outcome is the proportion of hypertension management visits at which guideline-based treatment is provided. In a separate sub-study conducted within the CDSS, with the patient as the unit of randomization, the LIGHT-ACD trial, patients are randomized to receive different initial mono- or dual- antihypertensive therapy. The primary outcome of the

LIGHT-ACD trial is the change in blood pressure from the first visit after site randomization to 9 months.

Discussion: The LIGHT trial will provide evidence on the effectiveness of a CDSS for improving guideline adherence for hypertension management in primary care in China. The sub-study, LIGHT-ACD trial, will provide data on the effect of different initial antihypertensive regimens for blood pressure management in this setting.

Trial registration: ClinicalTrials.gov, identifier: LIGHT (NCT03636334) and

LIGHT-ACD (NCT03587103). Registered on 3 July 2018.

Keywords: Hypertension; Clinical decision support system; Pragmatic trial

1 BACKGROUND

- 2 Hypertension is the leading modifiable risk factor for death globally.¹ Over the past
- 3 decades, the number of individuals with hypertension is estimated to have increased
- 4 by 90%, with the majority of the increase occurring in low- and middle-income
- 5 countries.² In China, an estimated 244.5 million adults have hypertension, and only
- 6 about 15% of these individuals have adequate blood pressure control, resulting in
- 7 major health and economic burdens.³
- 8 Improving the performance of primary care providers, who play a key role in
- 9 managing hypertension, and ensuring their adherence to guideline-recommended
- 10 antihypertensive treatments are public health priorities in China.⁴ Despite decade-long
- 11 efforts to improve the primary care system,⁵ there are quality issues^{3, 6}, and decision
- 12 support tools may help bridge this gap.^{4, 7} Traditional strategies to improve care,
- 13 including training sessions have only yielded modest effects.⁸ Furthermore, such
- 14 interventions are often difficult to implement widely because retraining of providers is
- 15 resource-intensive.^{4, 7, 9} The barriers to adequate management of hypertension in
- 16 China have led to calls for the implementation of computerized clinical decision
- 17 support system (CDSS) to improve performance and aid compliance with guidelines.^{4,}
- ⁹ Such systems are characterized by computerized algorithms that generate
- 19 guideline-based recommendations, and hence have the potential to improve
- 20 appropriate medication prescribing. However, prior studies assessing the
- 21 effectiveness of CDSS have shown mixed results.¹⁰⁻¹³ A scalable CDSS integrated
- 22 into primary care settings could improve the performance of providers and mitigate Page 5 of 41

1 the burden of hypertension in China and other countries.

2	In addition, in the course of testing the CDSS, there is an opportunity to test different
3	regimens. Blood pressure guidelines endorse a range of therapies as equivalent even
4	though there are a paucity of head-to-head comparisons. Treatment options
5	supported by previously published clinical trials or meta-analysis include
6	angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB),
7	calcium channel blockers (CCB), or thiazide/thiazide-like diuretics. ^{14, 15} Although the
8	blood pressure lowering effects of these antihypertensive medication classes are well
9	documented, there are differences in individual tolerability and drug-drug
10	interactions. ^{14, 16, 17} The CDSS pragmatic trial to promote guideline adherence can
11	rotate medication recommendations so that there is a nested trial comparing different
12	guideline-endorsed regimens.
13	Accordingly, we developed a CDSS for hypertension management and designed a
14	pragmatic, cluster-randomized controlled trial, the Learning Implementation of
15	Guideline-based decision support system for Hypertension Treatment (LIGHT) trial, to
16	assess its effectiveness for improving antihypertensive management in primary care
17	in China. Within the framework of LIGHT trial, the LIGHT-ACD trial aims to test
18	alternative, guideline-recommended regimens for blood pressure reduction.
19	
20	METHODS/DESIGN

21 The LIGHT trial

Page **6** of **41**

- 1 The LIGHT trial is a pragmatic, parallel-group, four-stage, cluster-randomized
- 2 controlled trial assessing the effectiveness of CDSS, with primary care practices as
- 3 the unit of randomization. (Supplement 1) The protocol is reported according to the
- 4 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
- 5 checklist¹⁸ (**Additional file 1**).
- 6 In each stage, up to 36 urban primary care practices were to be randomized to having
- 7 the CDSS embedded into their existing electronic health care record (EHR) or to
- 8 continue use of the EHR without the CDSS. During the first three months after
- 9 randomization, patients who attend the clinic for hypertension management are
- 10 screened for eligibility (see below) and if eligible asked to attend the clinic at least
- 11 every 3 months with data collected at each visit.¹⁹ (**Figure 2**)
- 12 Urban primary care practices with hypertension clinics were eligible to be included if:
- 13 (1) at least one agent from each of the four classes of antihypertensive medication
- 14 was available for prescription (ACE-inhibitor/ARB, beta-blocker, CCB,
- 15 thiazide/thiazide-like diuretic); (2) an EHR was being used for hypertension
- 16 management providing a structured template for collection of patient data; and (3) at
- 17 least 100 patients with hypertension were routinely being seen. Primary care
- 18 practices selected for each stage were randomized to the intervention (CDSS) or
- 19 control arm (usual care) in a 1:1 stratified by the baseline appropriate
- 20 (guideline-based) antihypertensive treatment rates and site characteristics
- 21 (Supplement 2).

Page 7 of 41

1

2 The Computer Decision Support System (CDSS)

3	The CDSS is a software algorithm which was developed by a multidisciplinary team
4	including clinicians and information technology experts. The CDSS uses information
5	recorded in the EHR and measurements taken at the visit to make recommendations
6	about the antihypertensive treatment for the patient. The recommendations are based
7	on the Chinese primary care hypertension guidelines ¹⁹ but are generally consistent
8	with international guidance ^{20, 21} and include a recommendation to add one or more of
9	the 4 classes of medication at half or full dose (Supplement 4). The logic of the CDSS
10	was tested using simulated patient data to trigger each possibility. In order to ensure
11	that the intervention is being reliably delivered to and used by doctors, clicking the
12	icon is designed to be mandatory before documentation of the prescription. If the
13	doctor decides not to follow the recommendation, a pop-up message stating "your
14	prescription did not match with CDSS recommendation, please re-evaluate the
15	classes/doses/frequencies of drugs." and prescriptions can be modified accordingly. If
16	the doctor decides not to follow the CDSS recommendation, relevant reasons (e.g.,
17	doctor preference or patient refusal) is recorded. In addition, if prescriptions involve
18	contraindicated drugs, under-dosing, or over-dosing, a message is also triggered.
19	
20	In control sites the EHR is used to record the same information but no treatment
21	recommendation is made and prescribing decisions are made by doctors based on
22	their knowledge and usual practice and recorded in the EHR.

23

Page **8** of **41**

1 Eligibility

- 2 Local residents aged ≥18 years with established hypertension attending the clinic are
- 3 eligible for the LIGHT trial if they are taking 0–2 classes of antihypertensive
- 4 medication. Major exclusion criteria include: (1) history of coronary heart disease,
- 5 heart failure, or chronic kidney disease; or (2) intolerance to ≥2 classes of
- 6 antihypertensive medications (Table 1). As the visit is the observation unit for the
- 7 primary and secondary outcomes, visits involving treatment of hypertension
- 8 (hypertension visits) of eligible patients are included in the analysis (**Supplement 3**).
- 9

10 Data collection, quality control, and management

- 11 To improve the workflow patient data are collected via the customized EHR, which
- 12 only collects information necessary for hypertension management (Table 2). Blood
- 13 pressure is measured in the sitting position after at least a 5-minute rest, with a
- 14 validated automated sphygmomanometer (Omron HBP-1300)²². Two blood pressure

15 readings are taken 1–2 minutes apart and the average value is recorded.

16

A bespoke website was developed to monitor progress and quality of the trial in real time. The CDSS recommendations are regularly reviewed via the website to ensure that the CDSS is working as designed. In addition, on-site audit of data collection is regularly conducted by the research team. To ensure the accuracy of documentation of the blood pressure values, values in the EHR are randomly selected (at least one value per site) and checked on a daily basis against the recordings in the blood

1 pressure monitor.

- 2
- 3 All data are securely transmitted to the central server through automatic electronic
- 4 transfer and securely stored in an encrypted and password-protected database. Data
- 5 confidentiality policies on data collection, storage, and analysis have been strictly
- 6 imposed in order to ensure the confidentiality of personal information.
- 7

8 Outcomes

- 9 The primary outcome for the LIGHT trial is the proportion of hypertension visits during
- 10 which appropriate antihypertensive treatment is prescribed. Appropriate
- 11 antihypertensive treatment is defined as a prescription compliant with the
- 12 pre-specified guideline-based recommendations (see detailed recommendations
- 13 specifications in **Supplement 5**).
- 14
- 15 The secondary outcomes include the average change in systolic blood pressure, the
- 16 proportion of those whose blood pressure is controlled at 9 months, and the
- 17 proportion of hypertension visits with *acceptable* antihypertensive treatment, which is
- 18 defined as either appropriate antihypertensive treatment (as above) or those
- 19 treatments with acceptable reasons for failing to titrate antihypertensive treatment. An
- 20 exploratory outcome is the number of patients experiencing a vascular event defined
- as a composite of cardiac death, non-fatal stroke, and non-fatal myocardial infarction.
- 22 (**Table 3**)

Page **10** of **41**

1

2 Sample size

3	As this is a staged pragmatic trial, we have the capacity to add sites as the trial
4	progresses. Initial statistical power was based on the number of sites potentially
5	eligible in stage 1 at the time the power analysis was being conducted; thus, we
6	assumed that at least 10 primary care practices would be randomized to the
7	intervention arm and 10 to the control arm, the baseline appropriate treatment rate
8	would be 55% with maximum type II error of α =0.05, a moderate intra-site correlation
9	of 0.05, a within-patient correlation of 0.1, and statistical power of 90%, we needed 3
10	hypertension visits per patient for 50 patients at each site in order to detect a 18%
11	absolute difference in appropriate treatment rate between the two arms. Subsequent
12	enrollment increased the number of participating sites to 94, randomized in 4 waves;
13	under the same assumptions as above we anticipate that the final sample will provide
14	90% power to detect a true difference of 4% in appropriate treatment rate. This
15	difference is close to the average effect of CDSS in improving process of care in prior
16	studies. ²³
17	

18 Statistical analysis

The analyses and reporting of the results will follow the Consolidated Standards of Reporting Trials guidelines for cluster randomized controlled trials.²⁴ All the analyses will be performed on an intention-to-treat basis. Multiple imputation by chained equations will be used to account for missing values.

Page **11** of **41**

2	With all comparative outcomes, absolute differences between the intervention and
3	control sites with 95% CIs will be presented. Implementation stages will be treated as
4	strata, with adjustment for calendar time to account for secular trends. The analysis of
5	both primary and secondary outcomes will account for the clustering effect using
6	mixed-effects models with site as a random effect. The consistency of treatment
7	effects on the primary outcome will be explored in predefined subgroups, including
8	age, gender, education, implementation stage, and tertile of cluster-level endpoints.
9	All statistical tests will be performed using 2-sided tests at the 0.05 level of
10	significance but the number of tests and p value will be taken into account in the
11	interpretation of the results
12	
13	The LIGHT-ACD trial
14	The LIGHT-ACD trial is an individually randomized sub-study embedded into the
15	intervention sites of LIGHT trial. In this sub-study, patients are randomized to receive
16	various initial antihypertensive therapies and blood pressure changes between
17	different regimens are compared (Figure 2).
18	
19	Recruitment
20	The patients at the intervention sites of LIGHT trial are eligible if they have a
21	measured baseline SBP \geq 140 mm Hg, and are taking 0–1 class of antihypertensive
22	medication. Key exclusion criteria include diabetes mellitus and intolerance to at least
23	one of the four class of antihypertensive medications (Table 1). The eligible patients in
	Page 12 of 41

- 1 the LIGHT-ACD trial are categorized into 2 subpopulations. Patients with a SBP of
- 2 140–159 mm Hg who are not taking any antihypertensive medication are categorized
- 3 as Population 1, the remainder as Population 2.
- 4

5 Randomization

- 6 Populations 1 and 2 are randomized separately (Figure 1). Population 1 individuals
- 7 are randomized to receive one of the initial monotherapies of A (ACE-inhibitor or ARB),
- 8 C (CCB), or D (diuretics). If additional treatment is needed, they are further
- 9 randomized to add either C or D so patients initiated with A are follow either
- 10 A-AC-ACD or A-AD-ADC with C and D as the add-on medications, respectively. The
- 11 randomization of protocols among patients initiated with C or D is similar to patients
- 12 initiated with A. Population 2 are randomized to receive one of the three initial dual
- 13 therapies of AC, AD, or CD. Subsequently, D, C, or A is added to achieve blood
- 14 pressure control, if necessary, respectively (Figure 1). Minimization randomization is
- 15 used to ensure balance on age, gender and education level among the three arms of
- 16 each populations.²⁵ Neither patients nor physicians are blinded to treatment allocation
- 17 but the allocation is concealed within the CDSS.
- 18

19 Treatment

- 20 The assignment of treatment is presented as the CDSS recommendation (class and
- 21 dose). The specific agent within each class is at the physician's discretion based on
- 22 the available medications of the practice. For each case, the titration of

- 1 antihypertensive medication is performed automatically by the CDSS according to the
- 2 assigned treatment protocol.
- 3

4 Outcomes

- 5 The primary outcome is the difference in the change in blood pressure from baseline
- 6 to 9 months between different regimens of initial therapy. Secondary outcomes
- 7 include the proportion of individuals with blood pressure controlled at 9 months; the
- 8 proportion of individuals with SBP <160 mm Hg and DBP <100 mm Hg at 9 months;</p>
- 9 the proportion of individuals who received monotherapy (only in Population 1), dual
- 10 therapy, triple therapy, and referral at 9 months; the proportion of individuals reported
- 11 to have antihypertensive drug-related side-effects; and the proportion of individuals
- 12 transferred to usual care for any reasons. The exploratory outcome is the change in
- 13 blood pressure from baseline to 9 months of six protocols embedded in the CDSS
- 14 (A-AC-ACD; A-AD-ADC; C-CA-CAD; C-CD-CDA; D-DC-DCA; D-DA-DAC). (Table 3)

15

16 Sample size

We assume approximately 25% of the LIGHT intervention patients are in Population 1 and 75% in Population 2, with an 80% follow-up rate for the primary outcome. For each population, we estimate the detectable difference in SBP between treatment groups across a similar range of the intervention participants and statistical power. We assume that the standard deviation in SBP is σ =10 mmHg, and that the within-patient SBP correlation is R²=0.2 with a maximum type II error that is Sidak-corrected for three comparisons, α =0.017.²⁶ With the current number of LIGHT sites, we estimate Page 14 of 41

1 about 2100 eligible LIGHT-ACD participants overall with complete follow-up. Under

- 2 these assumptions, we estimate that for the comparisons of initial monotherapies of A,
- 3 C, and D in Population 1, we will have 80% power to detect a difference of 3.5 mm Hg
- 4 in SBP, and for comparisons of dual therapies of AC, AD, and CD in Population 2, we
- 5 have 80% power to detect a difference of 2 mm Hg in SBP.
- 6

7 Statistical analysis

- 8 All the intervention evaluations will be performed on an intention-to-treat basis.
- 9 Multiple imputation by chained equations will be used to account for missing values.
- 10 For primary outcomes, we will use a linear regression model with indicators for
- 11 treatment regimen and practice, and will adjust for baseline blood pressure values
- 12 and imbalanced patient characteristics. Multiple Student t tests or Mann-Whitney U
- 13 tests will be used; P values will be adjusted for multiple comparisons by using the
- 14 Sidak method. For secondary outcomes, log-binomial regression will be used to
- 15 compare groups and calculate relative risk of outcomes at 9 months. Additionally, we
- 16 will perform pre-specified subgroup analyses of outcomes by age, sex, education,
- 17 smoking status, and tertile of baseline blood pressure. Considering potential
- 18 crossovers among treatments, we will also assess the heterogeneity of the treatment
- 19 effect among per-protocol populations.
- 20

21 DISCUSSION

22 The LIGHT trial is, to the best of our knowledge, the largest pragmatic randomized

Page **15** of **41**

1	trial exploring the feasibility and effectiveness of a decision support tool to deliver
2	high-quality care for hypertension in primary care. Moreover, by adopting a
3	streamlined study design, we have embedded a patient-level randomized trial
4	(LIGHT-ACD trial) into this cluster-randomized trial using an algorithm-based CDSS
5	tool.
6	
7	Our studies have several strengths. First, we have developed a usable CDSS, which
8	can easily be integrated into the routine clinical workflow and provides tailored
9	antihypertensive recommendations at the point of care. These features are highly
10	correlated with the effectiveness of CDSS for improving the process of care and
11	patient outcomes. ^{23, 27, 28} As recommendations of CDSS are generated automatically
12	by the built-in algorithm, which is developed based on current guidelines, this
13	approach can assist primary care doctors, even those with less training, in making
14	informed and evidence-based prescribing decisions.
15	
16	Second, we have built a streamlined framework for a clinical trial that enabled us to
17	compare the effectiveness of several guideline-based initial antihypertensive
18	regimens. Earlier randomized clinical trials such as the ALLHAT ¹⁵ and
19	ACCOMPLISH ²⁹ trials, provided a direct comparison among several monotherapies or
20	dual therapies. These trials are not contemporary and did not include large Asian
21	populations, so there remain gaps in knowledge. In contrast with these standalone
22	trials, the conduct of the LIGHT-ACD trial is embedded into the existing framework of
	Page 16 of 41

1	the LIGHT trial.	We incorporate a series of	of stepped treatment	protocols into the CDSS,

- 2 whereby the random allocation of recommended medication can be performed
- 3 automatically by following the algorithm-consistent order at each encounter where
- 4 decision support is delivered.³⁰ While assessing the effectiveness of CDSS, the
- 5 effectiveness of common initial antihypertensive monotherapies or dual therapies can
- 6 be compared in an unobtrusive manner.^{17, 29, 31, 32}
- 7
- 8 Third, the pragmatic design of both trials enables us to demonstrate real-world
- 9 effectiveness of intervention/treatment with greater external validity.^{33, 34} In contrast to
- 10 trials with study-specific visits, the enrollment and follow-up of patients, and the
- 11 collection of outcome data in our trial are incorporated into routine clinical practice.
- 12 Furthermore, the exclusion criteria are kept to a minimum to enroll a diverse spectrum
- 13 of the population. These considerations improve the efficiency of trials and enhance
- 14 generalizability of the study results.³⁴
- 15

16	Fourth,	the t	wo st	tudies	are	further	distinc	uisheo	d by	the	efforts	to	build	а	learnir	nq

- 17 decision support tool. Although the algorithm of CDSS is kept consistent during the
- 18 four stages of the trial, it has the potential to be adaptively updated after the results of
- 19 the LIGHT-ACD trial is available. For the ultimate implementation of the CDSS, the
- 20 tool could continuously generate new knowledge in terms of the effectiveness of
- 21 treatment strategies from the ongoing delivery of care, whereby the CDSS could be
- 22 iteratively tested and improved by shifting the randomization ratio of stepped

```
Page 17 of 41
```

- 1 antihypertensive protocols toward the more effective group.³⁵
- 2

3	Our study has some potential limitations. First, the outcomes are focused on
4	surrogate outcomes and not clinical outcomes such as cardiovascular events. To
5	examine the effectiveness on clinical events, a much longer trial would be required.
6	However, it is expected that improvements in blood pressure control over time would
7	favorably affect clinical outcomes. Second, given the nature of the CDSS, which
8	delivers its recommendation directly to doctors, blinding was not feasible in both
9	studies. We minimized the potential bias by using objective measures as primary and
10	secondary outcomes. Third, due to the limited timeframe of the study, an extended
11	follow-up was not included following the 12-month intervention to measure
12	persistence of effects after the intervention ceases.
13	
14	In conclusion, both trials should be able to provide useful evidence regarding the
15	effectiveness of this decision support tool on improving adherence to guidelines for
16	hypertension management in primary care, and on the comparative effectiveness of
17	different initial antihypertensive regimens for blood pressure reduction in the
18	real-world setting.
19	
20	TRIAL STATUS

- 21 Protocol version 4.4 commenced on December 28, 2020. As of May 2021, 94 sites
- 22 (including 7,656 patients in LIGHT and 494 participants in the LIGHT-ACD trial) have

Page **18** of **41**

- 1 been randomized in 4 stages. Site randomization of Stage 1 was on 21 August 2019,
- 2 Stage 2 on 4 December 2019, Stage 3 on 1 March 2021 and Stage 4 on 14 April 2021.
- 3 All sites will complete follow-up by the beginning of 2022. In the first half of 2020, the
- 4 implementation of both trials was affected by the outbreak of COVID-19. We extended
- 5 the study period of the first and second stages.
- 6

7 LIST OF ABBREVIATIONS

- 8 CDSS: computerized clinical decision support systems; EHR: electronic health record;
- 9 ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; CCB:
- 10 calcium channel blockers; A: angiotensin-converting enzyme inhibitor or angiotensin
- 11 receptor blocker; C: calcium channel blocker; D: diuretics.
- 12

13 **DECLARATIONS**

14 Ethics approval and consent to participate

- 15 The ethics committee of Fuwai Hospital approved both trials. All sites accepted this
- 16 ethics approval or obtained local approval by internal ethics committees as
- 17 appropriate. Given that guideline-based recommendations provided by CDSS was
- 18 considered to have minimal risk for the patients, informed consent for implementing
- 19 the CDSS in both trials is waived. A simple written informed consent for participants
- 20 was acquired for the purpose of sending a text message as a brief medical record
- 21 (e.g., blood pressure, prescriptions and follow-up reminders) after each visit.
- 22

23 Consent for publication

Page **19** of **41**

- 1 Not applicable.
- 2

3 Availability of data and materials

- 4 The datasets used and/or analysed during the current study will be available from the
- 5 corresponding author on reasonable request.
- 6

7 Competing interests

- 8 Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services
- 9 to support quality measurement programs; was a recipient of a research grant,
- 10 through Yale, from Medtronic and the US Food and Drug Administration to develop
- 11 methods for post-market surveillance of medical devices; was a recipient of a
- 12 research grant with Medtronic and is the recipient of a research grant from Johnson &
- 13 Johnson, through Yale University, to support clinical trial data sharing; was a recipient
- 14 of a research agreement, through Yale University, from the Shenzhen Center for
- 15 Health Information for work to advance intelligent disease prevention and health
- 16 promotion; collaborates with the National Center for Cardiovascular Diseases in
- 17 Beijing; receives payment from the Arnold & Porter Law Firm for work related to the
- 18 Sanofi clopidogrel litigation, from the Martin/Baughman Law Firm for work related to
- 19 the Cook IVC filter litigation, and from the Siegfried and Jensen Law Firm for work
- 20 related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth;
- 21 was a participant/participant representative of the IBM Watson Health Life Sciences
- Board; is a member of the Advisory Board for Element Science, the Advisory Board

Page **20** of **41**

1	for Facebook, and the Physician Advisory Board for Aetna; and is the founder of
2	HugoHealth, a personal health information platform, and co-founder of Refactor
3	Health, an enterprise healthcare AI-augmented data management company. Dr. Jing
4	Li discloses that she is a recipient of research grants from the government of China,
5	through Fuwai Hospital, for research to improve the management of hypertension and
6	blood lipids, and to improve care quality and patient outcomes of cardiovascular
7	disease; is a recipient of research agreements with Amgen, through National Center
8	for Cardiovascular Diseases (NCCD) and Fuwai Hospital, for a multi-centre trial to
9	assess the efficacy and safety of Omecamtiv Mecarbil, and for dyslipidemic patient
10	registration; is a recipient of a research agreement with Sanofi, through Fuwai
11	Hospital, for a multi-centre trial on the effects of sotagliflozin; is a recipient of a
12	research agreement with University of Oxford, through Fuwai Hospital, for a
13	multi-centre trial of empagliflozin; and was a recipient of a research agreement,
14	through NCCD, from AstraZeneca for clinical research methods training.
15	
16	Funding
17	This project was supported by the CAMS Innovation Fund for Medical Science
18	(2016-I2M-1-006) and the 111 Project (B16005) from the Ministry of Education of
19	China. These funding have no role in the design of the study, collection, analysis, or
20	interpretation of data or in writing the manuscript.
21	

22 Authors' contributions

Page **21** of **41**

1	HMK, JA, and XZ designed the study. XZ acted as the principal investigator to take
2	responsibility for all respect of the study. JS, HMK, JA, and XZ conceived of this article.
3	JS wrote the manuscript with further contributions from XZ, JA, HMK, JH, JW, JC, JL,
4	XL, HZ, JL, BW, XW and YG. JH calculated the sample size and provided advice in
5	randomization method of the study. YG performed daily data monitoring and
6	completed all the statistical analysis. XZ, LJ, HZ, JS, XW, and BW developed the
7	algorithm of the CDSS. All authors contributed to critical revisions and approved the
8	final version of the article.
9	
10	Acknowledgements
11	We appreciate the steering committee member of the study: Robert Clarke from
12	University of Oxford, Sharon-Lise T. Normand from the Harvard T.H. Chan School of
13	Public Health, Frederick A. Masoudi from University of Colorado School of Medicine,
14	Songtao Tang from the Community Health Center of Liaobu County, Wenjun Ma from
15	the Fuwai Hospital, and Jian Xu from the Center for Chronic Disease Control of
16	Shenzhen for their support and advice. We thank Lawrence J. Fine and George A.
17	Mensah from National Institutes of Health for their contributions in study design. We
18	appreciate the multiple contributions made by study teams at the National Clinical
19	Research Center of Cardiovascular Diseases in the realms of study design and
20	operation, particularly site management and coordination by Bo Gu, Yilan Ge, Fuyu
21	Jing, Lei Bi, Huijun Jin, Teng Li, and Liyuan Sui, and IT development and maintenance
22	by Shuyang Hua and Mengnan Zhu. We thank the local sites in the collaborative

Page **22** of **41**

- 1 network for their support and data collection.
- 2
- 3
- 4

1 **REFERENCES**

- 2 1. Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national
- 3 comparative risk assessment of 84 behavioural, environmental and occupational, and
- 4 metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a
- 5 systematic analysis for the Global Burden of Disease Study 2017. Lancet (London,
- 6 England). Nov 10 2018;392(10159):1923-1994. doi:10.1016/s0140-6736(18)32225-6
- 7 2. Bin Zhou, James Bentham, Cesare Mariachiara D, et al. Worldwide trends in
- 8 blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based
- 9 measurement studies with 19.1 million participants. The Lancet. 2017-01-01
- 10 2017;389(10064):37-55. doi:10.1016/s0140-6736(16)31919-5
- 11 3. Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China. *Circulation*.
- 12 2018;137(22):2344-2356. doi:doi:10.1161/CIRCULATIONAHA.117.032380
- 13 4. Li X, Krumholz HM, Yip W, et al. Quality of primary health care in China:
- 14 challenges and recommendations. *The Lancet.* 2020;395(10239):1802-1812.
- 15 doi:10.1016/s0140-6736(20)30122-7
- 16 5. Chen Z. Launch of the health-care reform plan in China. Lancet (London,
- 17 *England*). 2009;373(9672):1322.
- 18 6. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of
- 19 hypertension in China: data from 1.7 million adults in a population-based screening
- 20 study (China PEACE Million Persons Project). Lancet (London, England).
- 21 2017;390(10112):2549.
- 22 7. Li X, Lu J, Hu S, et al. The primary health-care system in China. Lancet (London,

- 1 *England*). 2017;390(10112):2584.
- 2 8. Rowe AK, Rowe SY, Peters DH, Holloway KA, Chalker J, Ross-Degnan D.
- 3 Effectiveness of strategies to improve health-care provider practices in low-income
- 4 and middle-income countries: a systematic review. The Lancet Global Health.
- 5 2018;6(11):e1163-e1175. doi:10.1016/s2214-109x(18)30398-x
- 6 9. Liang W, Binns CW, Lee AH. Computerised clinical decision support in rural
- 7 China. The Lancet. 2009;373(9657):30. doi:10.1016/s0140-6736(08)61955-8
- 8 10. Montgomery AA. Evaluation of computer based clinical decision support system
- 9 and risk chart for management of hypertension in primary care: randomised controlled
- 10 trial. *BMJ (Clinical research ed)*. 2000;320(7236):686-690.
- 11 doi:10.1136/bmj.320.7236.686
- 12 11. Bosworth H, Olsen M, Dudley T, et al. Patient education and provider decision
- 13 support to control blood pressure in primary care: a cluster randomized trial. Am Heart
- 14 *J*. 2009;157(3):450-6.
- 15 12. Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through
- 16 provider education, provider alerts, and patient education: a cluster randomized trial.
- 17 Annals of internal medicine. Aug 1 2006;145(3):165-75.
- 18 13. Hicks LS, Sequist TD, Ayanian JZ, et al. Impact of computerized decision support
- 19 on blood pressure management and control: a randomized controlled trial. Journal of
- 20 general internal medicine. Apr 2008;23(4):429-41. doi:10.1007/s11606-007-0403-1
- 21 14. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane
- 22 Database of Systematic Reviews. 2018;doi:10.1002/14651858.cd001841.pub3

- 1 15. The Allhat O, Coordinators For The Allhat Collaborative Research G. Major
- 2 Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting
- 3 Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and
- 4 Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA: The Journal
- 5 of the American Medical Association. 2002;288(23):2981-2997.
- 6 doi:10.1001/jama.288.23.2981
- 7 16. Law MR. Value of low dose combination treatment with blood pressure lowering
- 8 drugs: analysis of 354 randomised trials. *BMJ (Clinical research ed)*.
- 9 2003;326(7404):1427-0. doi:10.1136/bmj.326.7404.1427
- 10 17. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative
- 11 effectiveness and safety of first-line antihypertensive drug classes: a systematic,
- 12 multinational, large-scale analysis. *The Lancet*. 2019;394(10211):1816-1826.
- 13 doi:10.1016/s0140-6736(19)32317-7
- 14 18. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining
- 15 standard protocol items for clinical trials. *Annals of internal medicine*.
- 16 2013;158(3):200-207.
- 17 19. Office for Management of Hypertension in Primary Health Care NEPHSP.
- 18 National Hypertension Prevention and Management Guidelines for Primary Health
- 19 Care. Chinese Circulation Journal. 2017;(11)
- 20 20. Whelton PK, Carey RM, Aronow WS, et al. 2017
- 21 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
- 22 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:

Page **26** of **41**

- 1 Executive Summary: A Report of the American College of Cardiology/American Heart
- 2 Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex :
- 3 1979). Jun 2018;71(6):1269-1324. doi:10.1161/hyp.0000000000000066
- 4 21. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the
- 5 Management of High Blood Pressure in Adults: Report From the Panel Members
- 6 Appointed to the Eighth Joint National Committee (JNC 8). JAMA.
- 7 2014;311(5):507-520. doi:10.1001/jama.2013.284427
- 8 22. Meng L, Zhao D, Pan Y, et al. Validation of Omron HBP-1300 professional blood
- 9 pressure monitor based on auscultation in children and adults. BMC Cardiovasc
- 10 Disord. Jan/13 2016;
- 11 23. Kwan JL, Lo L, Ferguson J, et al. Computerised clinical decision support systems
- 12 and absolute improvements in care: meta-analysis of controlled clinical trials. BMJ
- 13 (Clinical research ed). 2020:m3216. doi:10.1136/bmj.m3216
- 14 24. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement:
- 15 extension to cluster randomised trials. *Bmj.* Sep 4 2012;345:e5661.
- 16 doi:10.1136/bmj.e5661
- 17 25. Pocock SJ, Simon R. Sequential treatment assignment with balancing for
- 18 prognostic factors in the controlled clinical trial. *Biometrics*. 1975:103-115.
- 19 26. ZK. Š. Rectangular Confidence Regions for the Means of Multivariate Normal
- 20 Distributions. *Journal of the American Statistical Association*. 1967;62(318):626-633.
- 21 27. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice
- 22 using clinical decision support systems: a systematic review of trials to identify

- 1 features critical to success. BMJ. Apr/02 2005;
- 2 28. Bright TJ, Wong A, Dhurjati R, et al. Effect of clinical decision-support systems: a
- 3 systematic review. Ann Intern Med. Jul 3 2012;157(1):29-43.
- 4 doi:10.7326/0003-4819-157-1-201207030-00450
- 5 29. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus Amlodipine or
- 6 Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal of
- 7 *Medicine*. 2008;359(23):2417-2428. doi:10.1056/nejmoa0806182
- 8 30. Frieden TR, King SMC, Wright JS. Protocol-Based Treatment of Hypertension.
- 9 JAMA. 2014;311(1):21. doi:10.1001/jama.2013.282615
- 10 31. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high
- 11 cardiovascular risk treated with regimens based on valsartan or amlodipine: the
- 12 VALUE randomised trial. *The Lancet.* 2004;363(9426):2022-2031.
- 13 doi:10.1016/s0140-6736(04)16451-9
- 14 32. Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events
- 15 with calcium channel blocker-based combination therapies in patients with
- 16 hypertension: a randomized controlled trial. Journal of hypertension. Aug
- 17 2011;29(8):1649-59. doi:10.1097/HJH.0b013e328348345d
- 18 33. Ford I, Norrie J. Pragmatic Trials. *New England Journal of Medicine*.
- 19 2016;375(5):454-463. doi:10.1056/nejmra1510059
- 20 34. Mentz RJ, Hernandez AF, Berdan LG, et al. Good Clinical Practice Guidance and
- 21 Pragmatic Clinical Trials. *Circulation*. 2016;133(9):872-880.
- 22 doi:10.1161/circulationaha.115.019902

Page **28** of **41**

- 1 35. Horwitz LI, Kuznetsova M, Jones SA. Creating a Learning Health System through
- 2 Rapid-Cycle, Randomized Testing. 2019;381(12):1175-1179.
- 3 doi:10.1056/NEJMsb1900856
- 4


FIGURE LEGEND

Figure 1. Infrastructure of the LIGHT and LIGHT-ACD trials

Figure 2. Schedule of enrollment, intervention allocation and assessment of the LIGHT

trial using Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)

Figure 1. Infrastructure of the LIGHT and LIGHT-ACD trials



Population 1: Participants with systolic blood pressure (SBP) of 140–159 mm Hg, and were not taking any antihypertensive medication.

Population 2: Participants with SBP \geq 160 mm Hg and were not taking any antihypertensive medication or taking one antihypertensive medication which was not beta-blocker, or those with SBP 140–159 mm Hg and were taking one antihypertensive medication which was not beta-blocker.

A: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; C: calcium channel blocker; D: diuretic.

Figure 2. Schedule of enrollment, intervention allocation and assessment of the LIGHT

trial using Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)

	STUDY PERIOD								
	Baseline data collection	Allocation of clusters	Post-allocation						
TIMEPOINT	-3 mos	0 mos	0-3 mos	3 mos	6 mos	9 mos			
ENROLMENT:									
Eligibility screen			Х						
Informed consent			Х						
Allocation		Х							
INTERVENTIONS:									
Computerized clinical decision support system			+						
Usual care			+						
ASSESSMENTS:									
Patient characteristics	Х		х	Х	Х	Х			
Clinic visit information	Х		Х	Х	Х	х			

Table 1. Inclusion and exclusion criteria of participan	ts for LIGHT and LIGHT-ACD trials
---	-----------------------------------

Criteria	LIGHT	LIGHT-ACD
Inclusion	Local residents aged ≥18 years and with established	Participants from intervention sites of LIGHT study with
	hypertension	systolic blood pressure ≥140 mm Hg at the screening visit
	Taking 0–2 classes of antihypertensive medications	Not taking antihypertensive medication or taking only one which was not beta-blocker
Exclusion	History of coronary heart disease*, heart failure, and chronic kidney disease	Known/diagnosed diabetes mellitus
	Intolerance to ≥2 classes of antihypertensive medications	Intolerance to ≥1 class of antihypertensive medications
	Secondary hypertension (physician-diagnosed)	Home blood pressure (if available) below 135/85 mm Hg
	Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at the screening visit	
	Serious medical conditions (e.g., malignant cancer and hepatic dysfunction)	
	Currently in an acute episode of disease	
	Currently pregnant or breastfeeding, or planning a pregnant or breastfeeding during the study	
	Cognitive or communication disorders	

*Including angina, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, >50% stenosis of coronary artery, or positive stress test

	Baseline	Recruitment	Follow-up
Socio-demographics	\checkmark	\checkmark	\checkmark
(age, gender, education, and			
insurance)			
Physical measurements	\checkmark	\checkmark	\checkmark
(blood pressure, heart rate,			
waist, height, and weight)			
Self-reported home	\checkmark	\checkmark	\checkmark
monitoring blood pressure			
Cardiovascular risk factors	\checkmark	\checkmark	\checkmark
Co-morbidities	\checkmark	\checkmark	\checkmark
Hospitalizations		\checkmark	\checkmark
Adverse events		\checkmark	\checkmark
Current medications	\checkmark	\checkmark	\checkmark
Medication adherence*	\checkmark	\checkmark	\checkmark
Side-effects related to		√	\checkmark
antihypertensive medication			
CDSS recommendations [#]		√	√
Prescriptions	√	√	√
Reasons for not following		√	√
CDSS [#]			

Table 2. Data elements collected in baseline, recruitment, and follow-up

*Adherence to each antihypertensive medication is collected as three classes: regularly, intermittently, and rarely

[#]Only in the intervention sites of LIGHT trial

Table 3. Outcomes of LIGHT and LIGHT-ACD trials


Outcomes	LIGHT	LIGHT-ACD
Primary	Appropriate (guideline-based) antihypertensive treatment rate	Absolute change in blood pressure at 9 months of different
Frimary	Appropriate (guideline-based) antinypertensive treatment rate	regimens of initial therapy
Secondary	Abachuta abanga of averalia blood procedure at 0 months	Proportion of individuals with blood pressure controlled (SBP
	Absolute change of systolic blood pressure at 9 months	<140 mm Hg and DBP <90 mm Hg) at 9 months
	Blood pressure control rate (defined as SBP <140 mm Hg and	Proportion of individuals with SBP <160 mm Hg and DBP
	DBP <90 mm Hg) at 9 months	<100 mm Hg at 9 months
	Acceptable (appropriate/non-appropriate but with proper	Proportion of individuals who received monotherapy*, dual
	reasons) antihypertensive treatment rate	therapy, triple therapy, and referral at 9 months
		Proportion of individuals with antihypertensive drug
		side-effects
		Proportion of individuals transferred to usual care for any
		reason
	A composite of cardiac death, non-fatal stroke, and non-fatal	Absolute change in blood pressure at 9 months of different
Exploratory	myocardial infarction	protocols*

SBP, systolic blood pressure; DBP, diastolic blood pressure.

Primary and secondary outcomes of LIGHT-ACD were assessed among initiating therapies; exploratory outcomes of LIGHT-ACD were assessed among protocols.

*Only assessed in Population 1, who are not currently taking any antihypertensive medication with systolic blood pressure 140–159 mm Hg, and initiated with monotherapy

SUPPLEMENT



Supplement 1. Timeline of the LIGHT trial

Supplement 2. Stratification factors for each stage in site randomization of LIGHT trial

- Stage 1 (18 sites in Luoyang, Henan Province): baseline appropriate antihypertensive treatment rates of the site (≥median/<median) and the hospital to which the site is affiliated (Dongfang Hospital/Sixth People's Hospital/Zhongxin Central Hospital).
- Stage 2 (9 sites in Zoucheng, Shandong Province): baseline appropriate antihypertensive treatment rates of the site (≥median/<median) and type of primary care practice (Fenyuan/Community health service station).
- Stage 3 (31 sites in Shenzhen, Guangdong Province): baseline appropriate antihypertensive treatment rates of the site (≥median/<median) and geographical region (Baoan District/Nanshan District).
- Stage 4 (36 sites in Shenzhen, Guangdong Province): baseline appropriate antihypertensive treatment rates of the site (≥median/<median) and geographical region (Luohu District/Longgang District/Futian District).

Supplement 3. Specification of hypertension visits

Page **36** of **41**

- 1) Scheduled or unscheduled visits for treatment of hypertension
- Visit for diabetes, stroke, peripheral vascular disease, or other new cardiovascular diseases (i.e., chronic kidney disease, coronary heart disease, and heart failure).

Supplement 4. Example of CDSS recommendation

"The recommended antihypertensive medications are C+D

C (calcium channel blocker): full dose

D (diuretics): half dose"

Note: Full dose or half dose refer to one or half pill of commonly used antihypertensive medications respectively.

Supplement 5. Specifications of guideline-based antihypertensive treatment

- Uptitrating or switching treatment for patients with inadequate blood pressure control.
- Uptitrating or switching treatment for patients who: a) have systolic blood pressure (SBP) 140–159 mm Hg or diastolic blood pressure (DBP) 90–99 mm Hg; AND b) have established diagnosis of hypertension less than 3 months; AND c) have complications of hypertension (i.e., diabetes, chronic kidney diseases, stroke, myocardial infarction, and heart failure)
- Uptitrating or switching treatment for patients who: a) have SBP 140–159 mm
 Hg or DBP 90–99 mm Hg; AND b) have established diagnosis of
 hypertension more than 3 months; AND c) take no antihypertensive
 medications.
- Uptitrating or switching treatment for patients who: a) have SBP ≥160 mm
 Page 37 of 41

Hg or DBP ≥100 mm Hg; AND b) take no antihypertensive medications.

- Uptitrating or switching treatment for patients who: a) have SBP ≥140 mm
 Hg or DBP ≥90 mm Hg; AND b) take at least one antihypertensive
 medication.
- Antihypertensive medications used in patients with specific clinical indications for their use.
 - Use of beta-blockers for patients with myocardial infarction and heart failure.
- Use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) for patients with diabetes, chronic kidney disease, myocardial infarction, and heart failure.
- Antihypertensive medications used in patients without compelling contraindications for their use.
- Use of diuretics for patients without gout.
- Use of beta-blockers for patients without bradycardia (heart rate <50 beats/min).
- Use of angiotensin-converting enzyme inhibitors (ACEI) for patients without hyperkalemia (potassium >5.5 mmol/L) or previous angioneurotic edema.
- Use of angiotensin receptor blockers (ARB) for patients without hyperkalemia (potassium >5.5 mmol/L).
- 4) Antihypertensive medications used in patients without intolerance for their use
- Use of calcium channel blockers (CCB) for patients without intolerance (e.g., CCB-induced edema) to their use
- Use of ACEI for patients without intolerance (e.g., ACEI-induced cough) to their use

- 5) Use of guideline-based antihypertensive medication
- Any antihypertensive medications beyond ACEI, ARB, beta-blocker, CCB, and diuretics not used for patients with complications.
- Any antihypertensive medications beyond ACEI, ARB, beta-blocker, CCB, diuretics, compound reserpine triamterene, and compound reserpine) not used for patients without complications.
- 6) Other
 - Agents within the same class of antihypertensive medications not used at the same time.
 - Referral for patients with full dose of ACEI/ARB, CCB, and diuretics but with inadequate blood pressure control.
- Single use of short-acting antihypertensive medications with frequency compliance to that of specified in the instruction

Supplement 6. Trial registration data of the LIGHT trial

1. Primary Registry and Trial Identifying Number	ClinicalTrials.gov NCT03636334 (LIGHT)
2. Date of Registration in Primary Registry	3 July 2018
3. Secondary Identifying Numbers	Not applicable
4. Source(s) of Monetary or Material Support	CAMS Innovation Fund for Medical Science (2016-I2M-1-006)
5. Primary Sponsor	Chinese Academy of Medical Sciences and Peking Union Medical
	College
6. Secondary Sponsor(s)	Not applicable
7. Contact for Public Queries	Professor Xin Zheng
	National Clinical Research Center for Cardiovascular Diseases, State
	Key Laboratory of Cardiovascular Disease, Chinese Academy of
	Medical Sciences and Peking Union Medical College, Fuwai Hospital,
	National Center for Cardiovascular Diseases, Beijing, China
	xin.zheng@fwoxford.org
8. Contact for Scientific Queries	Professor Xin Zheng
	National Clinical Research Center for Cardiovascular Diseases, State
	Key Laboratory of Cardiovascular Disease, Chinese Academy of
	Medical Sciences and Peking Union Medical College, Fuwai Hospital,
	National Center for Cardiovascular Diseases, Beijing, China
	xin.zheng@fwoxford.org
9. Public Title	Rationale and design of the Learning Implementation of
	Guideline-based decision support system for Hypertension Treatment
	(LIGHT) Trial and LIGHT-ACD Trial
10. Scientific Title	Rationale and design of the Learning Implementation of
	Guideline-based decision support system for Hypertension Treatment
	(LIGHT) Trial and LIGHT-ACD Trial
11. Countries of Recruitment	China
12. Health Condition(s) or Problem(s) Studied	Hypertension
13. Intervention(s)	Intervention arm: computerized clinical decision support systems for
	hypertension management
	Control arm: usual care
14. Key Inclusion and Exclusion Criteria	See main body of protocol
15. Study Type	A pragmatic, parallel-group, four-stage, cluster-randomized controlled
	trial using stratified randomization
16. Date of First Enrollment	21 August 2019
17. Target Sample Size	94 sites
18. Recruitment Status	Recruiting
19. Primary Outcome(s)	Proportion of hypertension visits during which appropriate
	antihypertensive treatment is prescribed
20. Key Secondary Outcomes	Average change in systolic blood pressure, the proportion of those
	whose blood pressure is controlled at 9 months, and the proportion of
	hypertension visits with acceptable antihypertensive treatment

Supplement 7. Trial registration data of the LIGHT-ACD trial

1. Primary Registry and Trial Identifying Number	ClinicalTrials.gov NCT03587103 (LIGHT-ACD)	
2. Date of Registration in Primary Registry	3 July 2018	
3. Secondary Identifying Numbers	Not applicable	
4. Source(s) of Monetary or Material Support	CAMS Innovation Fund for Medical Science (2016-I2M-1-006)	
5. Primary Sponsor	Chinese Academy of Medical Sciences and Peking Union Medical College	
6. Secondary Sponsor(s)	Not applicable	
7. Contact for Public Queries	Professor Xin Zheng	
	National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China xin.zheng@fwoxford.org	
8. Contact for Scientific Queries	Professor Xin Zheng	
	National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China xin.zheng@fwoxford.org	
9. Public Title	Rationale and design of the Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) Trial and LIGHT-ACD Trial	
10. Scientific Title	Rationale and design of the Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) Trial and LIGHT-ACD Trial	
11. Countries of Recruitment	China	
12. Health Condition(s) or Problem(s) Studied	Hypertension	
13. Intervention(s)	Population 1: Initial monotherapy of A, C, and D Population 2: Initial dual-therapy of AC, AD, and CD	
14. Key Inclusion and Exclusion Criteria	See main body of protocol	
15. Study Type	A pragmatic, three-arm, patient-randomized trial using minimization randomization	
16. Date of First Enrollment	21 August 2019	
17. Target Sample Size	2100 patients	
18. Recruitment Status	Recruiting	
19. Primary Outcome(s)	Change in blood pressure from baseline to 9 months	
20. Key Secondary Outcomes	Proportion of individuals with blood pressure controlled at 9 months; the proportion of individuals with SBP <160 mm Hg and DBP <100 mm Hg at 9 months	